Dexmedetomidine Activates AMPK/SIRT1 Pathway to Reduce Inflammatory Levels and Neuronal Pyroptosis to Alleviate Neonatal Hypoxic-Ischemic Brain Damage.
Neonatal hypoxic-ischemic brain damage (HIBD) is the leading cause of neonatal death and long-term neurological dysfunction. Dexmedetomidine (DEX) has been shown to have neuroprotective effects, but its mechanisms in HIBD remain incompletely understood. This study aimed to explore whether DEX inhibits neuroinflammation...